

REMARKS

Reconsideration of the pending application is respectfully requested on the basis of the following particulars.

1. In the claims

Claims 1 and 12 are similarly amended to make explicit limitations which were considered implicit in the previously presented version of claims 1 and 12. Specifically, the proximal side of the wound dressing is now identified as the “bodyside” surface of the dressing. Support for this amendment is found in Figs. 6-8, and in the corresponding sections in the written description. The proximal surface is thus explained in claims 1 and 12 as being the outermost surface on the proximal side to make abundantly clear the nature of the bodyside surface.

The absorbent core is identified as having “peripheral edges” and the facing layer is particularly described as being delimited by the peripheral edges of the absorbent core. Support for this amendment is found in at least Figs. 2, 9 and 10, and in the corresponding sections in the written description.

New claim 27 is substantially similar to amended claim 1 with the exception of the last limitation describing at least one segment of a border portion of the facing layer corresponding to the border portion of the absorbent core, and further including the limitation that the apertures in the facing layer are formed irrespective of the proximal surface of the absorbent core. Support for this language is found in the written description at page 10, 1<sup>st</sup> full paragraph. It will be noted that this language with regard to the apertures is similar to the language used in allowed U.S. patent 7,230,154 (serial number 10/725,561) which claims the same priority of the instant application.

It is submitted that the amendment to the claims does not introduce new matter into the application. Entry and consideration of the amendment to the claims is respectfully requested.

2. Rejection of claims 1, 2, 5 and 7 under 35 U.S.C. 103(a) as being unpatentable over U.S. patent 5,160,328 (*Cartmell I*) in view of U.S. patents 4,657,006 (*Rawlings*), 6,051,747 (*Lindqvist*), 5,591,820 (*Kydonieus*) and 5,489,262 (*Cartmell II*)

Reconsideration of this rejection is respectfully requested in view of the amendment to claim 1 and the following observations. It is submitted that the proposed combination of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus* and *Cartmell II* fails to render these rejected claims obvious.

Turning to first *Cartmell I*, the primary reference the rejection attempts to modify, it is readily apparent from the amendment to the claims that *Cartmell I* does not disclose or suggest the facing layer required by the pending claims. The rejection points to support layer (16) and second support layer (17) as the equivalent to the facing layer of the pending claims. In observing Fig. 2, it is readily apparent from *Cartmell I* that layers (16, 17) are intermediate layers, and in no manner would it be understood by the skilled person that these layers (16, 17) form a “bodyside” surface of the wound dressing shown therein. Indeed, there is no “proximal” location to these layers since they are clearly located in between the backing layer (18) and the hydrogel layer (14).

The examiner is respectfully requested to review the written description of the pending application at page 10, 1<sup>st</sup> paragraph, which clearly points to what is meant by “proximal.” Indeed, the proximal side, as in the wound dressing at large, is defined as being close or adjacent to the wound or skin of the wearer of the wound dressing. As for the absorbent core, the proximal surface *p* is plainly defined as the side of the absorbent core closest to the wound or skin of the wearer of the wound dressing (see Fig. 2). The usage of “proximal” in the context of the facing layer in the specification is the same as the absorbent core, and is clearly depicted as being the bodyside surface of the dressing which is exposed to the wound or skin of the wearer of the wound dressing (see for example Figs. 6-8).

“Distal,” on the other hand, is readily understood as being opposite to the proximal surface. This is clearly exemplified in Fig. 2 of the pending application.

Consideration of the intended location of the “proximal” and “distal” sides or surfaces of the features recited in the claims and defined in the specification is respectfully requested for a full understanding of the claim language.

Next, it is not understood how the support layers (16, 17) in *Cartmell I* themselves form any sort of a skin adherent facing layer, as particularly required by claim 1. The rejection apparently ignores such a requirement by claim 1. Indeed, there are no “skin adherent properties” to the support layers (16, 17) since *Cartmell I* explains that an adhesive (15) is required to secure these support layers (16, 17) to one another (3:35-39).

The rejection explains that *Cartmell I* does not disclose the support layers (16, 17) as being formed of cross-linked silicone gel, and there is good reason for this omission; it makes no sense to make these support layers from silicone gel. These support layers are not intended to form a bodyside surface of the wound dressing, but are only provided between the backing layer (18) and the hydrogel layer (14) so as to provide additional support to the hydrogel layer (14) (3:42-44).

Next, *Cartmell I* does not disclose a facing layer forming a bodyside surface and having apertures. While the rejection equates the apertures formed in the backing layer (18) of the dressing in *Cartmell I* as the apertures recited by claim 1, it is abundantly clear that these apertures are not formed on a bodyside surface of the dressing. Instead, the apertures taught by *Cartmell I* are formed on a backside surface of the dressing. Even though an adhesive layer (20) is applied to the backing layer (18), the adhesive layer (20) is not located on the hydrogel layer (14) or provided only within the peripheral edges of the hydrogel layer (14).

From the amendment to claim 1, it should now be clear as to where the silicone gel facing layer and adhesive layer are located in regard to the absorbent core (i.e., the facing layer directly on the absorbent core so as to form the bodyside surface

of the wound dressing and within the peripheral edges of the absorbent core). It is submitted that *Cartmell I* clearly does not disclose such a construction.

Having made observations on *Cartmell I*, it is also submitted that the teachings of *Rawlings*, *Lindqvist*, *Kydoneius* and *Cartmell II* fail to make up for the shortcomings of *Cartmell I*.

*Rawlings* is apparently provided in the rejection to show that an intermediate layer in a wound dressing is perforated. Of course, as pointed out above, the facing layer of claim 1 does not require an intermediate facing layer, but instead requires a facing layer which forms a bodyside surface to the wound dressing. Thus, *Rawlings* does not make up for any of the shortcomings of *Cartmell I*.

Turning to *Lindqvist*, this reference merely teaches that a facing layer may be formed from a silicone gel, but fails to make up for the shortcomings of *Cartmell I*. *Lindqvist*, however, does not disclose the particular structure and location of the facing layer and pressure sensitive adhesive required by claim 1, including the additional provision of a pressure sensitive adhesive deposited over an area of a silicone gel facing layer without apertures.

In considering *Kydoneius*, this reference does not make up for any of the shortcomings of the other references used in this rejection. The rejection identifies teachings in *Kydoneius* that discuss the difference in tackiness between a pressure sensitive adhesive and a hydrocolloid. It will be pointed out that a hydrocolloid is not the same as a hydrophobic silicone gel. Appended herewith is a document entitled "Hydrocolloid dressings: Frequently Asked Questions" which explains that a hydrocolloid is a "gel-forming agent" which "absorbs liquid" to form a gel. On the contrary, a silicone gel is readily understood as being hydrophobic, and does not form upon absorbing liquid. Indeed, cured silicone gel is not affected by liquid unlike a hydrocolloid.

Lastly, *Cartmell II* is much like *Cartmell I*, and does not disclose a facing layer that forms the bodyside surface of a wound dressing that is directly secured to a

proximal surface of an absorbent core. Other than the hydrogel layer (42) itself, the only other skin-adherent layer in the wound dressing of *Cartmell II* is the adhesive (24) which only surrounds the hydrogel layer (42) along the bodyside surface of the wound dressing. Thus, *Cartmell II* fails to disclose these particular features omitted by *Cartmell I* and required by the pending claims.

There is simply no indication in either *Cartmell I* or *Cartmell II* of providing a facing layer on the hydrogel layer (42). As explained in *Cartmell II*, the skilled person would recognize that hydrogel has a gel-like consistency that creates a bond between the wound dressing and the wound site (6:27-30). The skilled person would understand the differences of hydrogel (which is absorptive or hydrophilic) and a silicone gel (which is hydrophobic), and would find not motivation to add a facing layer, of the type required by the pending claims, in addition to the hydrogel layer in either of *Cartmell I* or *Cartmell II*.

From these observations on the proposed combination of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus* and *Cartmell II*, it is submitted that this combination fails to meet all of the limitations required by amended claim 1. Accordingly, claim 1 is patentable over this combination, and the remaining claims in this rejection are patentable based on their dependency from claim 1 and their individually recited features.

Accordingly, withdrawal of this rejection is respectfully requested.

3. Rejection of claim 3 under 35 U.S.C. 103(a) as being unpatentable over U.S. patent 5,160,328 (*Cartmell I*) in view of U.S. patents 4,657,006 (*Rawlings*), 6,051,747 (*Lindqvist*), 5,591,820 (*Kydonieus*) and 5,489,262 (*Cartmell II*) and further in view of U.S. patent application publication 2003/2003/0199800 (*Levin*)

Reconsideration of this rejection is respectfully requested in view of the aforementioned observations in section (2) of these remarks, and the following observations on *Levin*.

*Levin* simply fails to disclose a facing layer that is directly secured to an absorbent core and delimited by the peripheral edges of the absorbent core, wherein a pressure sensitive adhesive is applied to the facing layer itself, as required by claim 1 from which claim 3 depends. Indeed, in observing Fig. 3, *Levin* discloses a plastic film (36) with an adhesive (40) which extends beyond the sides of the apertured gel-type material (22). Furthermore, it is plainly evident that the adhesive (36) and the gel-type material (22) in *Levin* are not contiguous, as particularly required by claim 1, since there is a gap between the adhesive (40) and the gel-type material (22).

From these observations on the proposed combination of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus*, *Cartmell II* and *Levin*, it is submitted that this combination fails to meet all of the limitations required by claim 3. Accordingly, claim 3 is patentable over this combination based on its dependency from claim 1 and its individually recited features.

Accordingly, withdrawal of this rejection is respectfully requested.

4. Rejection of claims 8 and 9 under 35 U.S.C. 103(a) as being unpatentable over U.S. patent 5,160,328 (*Cartmell I*) in view of U.S. patents 4,657,006 (*Rawlings*), 6,051,747 (*Lindqvist*), 5,591,820 (*Kydonieus*) and 5,489,262 (*Cartmell II*) and further in view of U.S. patent 5,653,699 (*Reed*)

It is submitted that *Reed* fails to make up for the aforementioned shortcomings of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus* and *Cartmell II*. It is submitted that this combination fails to meet all of the limitations required by claim 1, and the additional limitations of claim 8 and 9. Accordingly, claims 8 and 9 are patentable over this combination based on their dependency from claim 1 and their individually recited features.

Accordingly, withdrawal of this rejection is respectfully requested.

5. Rejection of claims 12, 15, 19 and 20 under 35 U.S.C. 103(a) as being unpatentable over U.S. patent 5,160,328 (*Cartmell I*) in view of U.S. patents

4,657,006 (Rawlings), 6,051,747 (Lindqvist), 5,591,820 (Kydonieus) and 5,489,262 (Cartmell II) and further in view of U.S. patent 5,653,699 (Reed)

This rejection is respectfully traversed based on the observations provided herein in sections (2) and (4). It submitted that the combination of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus*, *Cartmell II* and *Reed* fails to disclose every feature required by claims 12, 15, 19 and 20, as discussed above.

Accordingly, it is submitted that the combination of *Cartmell I*, *Rawlings*, *Lindqvist*, *Kydonieus*, *Cartmell II* and *Reed* fails to meet all of the limitations required by claim 12. Accordingly, claim 12 is patentable over this combination, and the remaining claims in this rejection are patentable based on their dependency from claim 12 and their individually recited features.

Accordingly, withdrawal of this rejection is respectfully requested.

6. New claim 27

This claim is patentable based on the shared limitations with claim 1, and for the limitation that the apertures of the facing layer are formed irrespective of the proximal surface of the absorbent core. This particular language was found to clearly distinguish the facing layer of the pending application from prior art teachings of silicone gel facing layers which are formed on the basis of the proximal surface of the absorbent core (i.e., *Lindqvist*).

Application No.: 10/725,601  
Examiner: Lewis, K. C.  
Art Unit: 3772

7. Conclusion

As a result of the amendment to the claims and the foregoing observations, it is respectfully submitted that the application is in condition for allowance. Accordingly, it is respectfully requested that the present application be allowed and the application be passed to issue.

If any issues remain that may be resolved by a telephone or facsimile communication with the applicant's attorney, the examiner is invited to contact the undersigned at the numbers shown below.

BACON & THOMAS, PLLC  
625 Slaters Lane, Fourth Floor  
Alexandria, Virginia 22314-1176  
Phone: (703) 683-0500  
Facsimile: (703) 683-1080

Date: November 26, 2007

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Justin J. Cassell", written in a cursive style.

JUSTIN J. CASSELL  
Attorney for Applicant  
Registration No. 46,205



# World Wide Wounds

## Frequently Asked Questions: Hydrocolloid Dressings

- Introduction
- What are hydrocolloid dressings?
- What are the main indications for hydrocolloid dressings?
- Are there any side effects of hydrocolloid dressings?
- How much fluid can hydrocolloid dressings absorb?
- What is the role of hydrocolloid dressings in maggot therapy?
- What is the role of hydrocolloids in hypertrophic scars and keloids?
- Have hydrocolloids been rendered obsolete by newer dressing types?
- Are hydrocolloid dressings cost effective?
- Do hydrocolloid dressings reduce pain?
- Is there any difference between brands?
- Is colour duplex imaging possible through hydrocolloid dressings?
- How effective are hydrocolloid dressings for partial thickness burns?
- Are hydrocolloid dressings contraindicated in diabetes?
- What are the effects of a hydrocolloid dressing on bacterial growth?

Andrew Heenan RGN, RMN, BA (Hons) [a.heenan@smtl.co.uk]

### Publishing details

Submitted: 27 February 1998

Edition 1.0 - Published: 08 April 1998.

Edition 1.1 - Minor corrections: 28 April 1998.

## Introduction

Hydrocolloids are among the most widely used modern dressings; but that does not necessarily mean that they are widely understood.

This article aims to provide answers to many of the questions that users might ask. It is *not* intended to be the final word; rather the opposite. These answers are written to be a starting point and no more. Like every article in *World Wide Wounds*, it can be amended or extended following readers' suggestions and additions.

## What are hydrocolloid dressings?

Hydrocolloids are a type of dressing containing gel-forming agents, such as sodium carboxymethylcellulose (NaCMC) and gelatin. In many products, these are combined with elastomers and adhesives and applied to a carrier - usually polyurethane foam or film, to form an absorbent, self adhesive, waterproof wafer.

In the presence of wound exudate, hydrocolloids absorb liquid and form a gel, the properties of which are determined by the nature of the formulation. Some dressings form a cohesive gel, which is largely contained within the adhesive matrix; others form more mobile, less viscous gels which are not retained within the dressing structure.

In the intact state most hydrocolloids are impermeable to water vapour, but as the gelling process takes place, the dressing becomes progressively more permeable. The loss of water through the dressing in this way enhances the ability of the product to cope with exudate production [1].

One feature of hydrocolloids that is appreciated by clinicians is wet tack; unlike most dressings, they can adhere to a moist site as well as a dry one.

**Reference 1:** Thomas S., Loveless, P. A comparative study of the properties of twelve hydrocolloid dressings. *World Wide Wounds*, July 1997; [Full Text: <http://www.smtl.co.uk/World-Wide-Wounds/1997/july/Thomas-Hydronet/hydronet.html>]

[^Top](#)

## What are the main indications for hydrocolloid dressings?

Hydrocolloids are easy to use, require changing only every 3-5 days, and do not cause trauma on removal. This makes them useful for clean, granulating, superficial wounds, with low to medium exudate.

Hydrocolloids provide effective occlusion; with dry wounds, they can have a softening effect, and they have been used to prevent the spread of MRSA (by providing a physical occlusive barrier).

**Reference:** Thomas, S., *Hydrocolloids Journal of Wound Care* 1992;1;2, 27-30

[^Top](#)

**Are there any side effects of hydrocolloid dressings?****Contact dermatitis**

Hydrocolloid wound dressings have been in use for some 20 years, and have rarely been associated with allergic contact dermatitis. However, some hydrocolloid dressings contain the pentaerythritol ester of hydrogenated rosin as a tackifying agent, and this substance retains the sensitizing potential of colophony.

*Reference:* Sasseville D, Tennstedt D, Lachapelle JM: Allergic contact dermatitis from hydrocolloid dressings. *Am J Contact Dermat* 1997 Dec;8(4):236-238

---

^Top

**How much fluid can hydrocolloid dressings absorb?**

The ability of hydrocolloids to absorb fluids varies considerably over time, and between products. Laboratory studies [1] suggest that the dressings may not be suitable for medium to high exuding wounds. Other research [2] suggested that when properly applied, the dressings might reduce the amount of exudate.

*Reference 1:* Thomas S., Loveless, P. A comparative study of the properties of twelve hydrocolloid dressings. *World Wide Wounds*, July 1997; [Full Text: <http://www.smtl.co.uk/World-Wide-Wounds/1997/july/Thomas-Hydronet/hydronet.html>]

*Reference 2:* Thomas S., Fear M., Humphreys J., Disley L., Waring MJ. The effect of dressings on the production of exudate from venous leg ulcers. *WOUNDS* 1996;8(5):145-150

**What is the role of hydrocolloid dressings in maggot therapy?**

Despite decades of experience in Maggot therapy, selecting appropriate dressing materials continues to be a problem. The dressing has to (1) prevent the maggots from escaping, (2) permit oxygen to reach the maggots, (3) facilitate drainage, (4) allow inspection of the wound, (5) require minimal maintenance, and (6) be of low cost.

One centre developed a two-layered cagelike dressing, the bottom layer of which comprised a hydrocolloid pad, applied to the surrounding healthy skin and covered by a fine chiffon or nylon mesh. Liquefied necrotic tissue drained through the mesh and was absorbed in a top layer of gauze, which was replaced periodically. Thus it was possible to contain the maggots within the wound by means of readily available materials.

*Reference:* Sherman R. A., A new dressing design for use with maggot therapy. *Plast Reconstr Surg* 1997 Aug;100(2):451-456

---

^Top

**What is the role of hydrocolloids in hypertrophic scars and keloids?**

Silicone gel sheeting has been investigated for use in the treatments of keloids and hypertrophic scars. Its mechanism of action may be related to scar hydration. One randomized controlled prospective study set out to evaluate a hydrocolloid occlusive dressing that also acts by promoting a moist environment. Scar size and volume, color, patient symptoms, and transcutaneous oxygen measurements were taken.

The study found significantly reduced itching, reduced pain and increased pliability for both treatments, used over two months. The authors concluded that hydration of the scar offered symptomatic improvement, but no change in physical parameters.

*Reference:* Phillips T. J., Gerstein A. D., Lordan V., A randomized controlled trial of hydrocolloid dressing in the treatment of hypertrophic scars and keloids. *Dermatol Surg* 1996 Sep;22(9):775-778

---

^Top

**Have hydrocolloids been rendered obsolete by newer dressing types?**

Over recent years, many new dressings have appeared on the market, but few new dressing types. The continuing success of hydrocolloids depends largely on their effectiveness as occlusive dressings. Any new dressing has to match or better their performance and/or compete on price. Currently, manufacturers of polyurethane foam dressings are promoting them as an alternative to hydrocolloids.

Few studies compare hydrocolloids with newer dressing types. In one randomised controlled clinical study involving 100 patients with leg ulcers and 99 patients with pressure sores in the community, a 'hydropolymer' dressing and a hydrocolloid dressing were compared. Statistically significant differences in favour of the hydropolymer dressing were detected for dressing leakage and odour production, but no statistically significant differences were recorded in the number of patients with either leg ulcers or pressure sores who healed in each treatment group.

The future may see hydrocolloids used more selectively, but they are by no means obsolete.

*Reference:* Thomas S., Banks V., Bale S., et al. A comparison of two dressings in the management of chronic wounds. *J Wound Care* 1997 Sep;6(8):383-386

[^Top](#)

### Are hydrocolloid dressings cost effective?

Studies too numerous to cite have established that hydrocolloid dressings are more effective than 'traditional' dressings, such as parafin gauze, dry gauze and saline soaks. Despite this, and the relative reduction in cost over the decades, many health professionals continue to use obsolete materials and methods.

When the efficacy of hydrocolloid occlusive dressing technique is compared with conventional wet-to-dry gauze dressing technique, the patient has been shown to benefit with a greater chance of healing, faster healing times, and less pain.

Nursing time is very significantly reduced, because the wound does not need dressing so often (or for so long) dressing time is markedly reduced. Costs are saved in materials alone, before even considering the cost of professional time [1]

Similar results have been found in patients with leg ulcers [2]

*Reference 1:* Kim Y.C., Shin J.C., Park C.I., et al. Efficacy of hydrocolloid occlusive dressing technique in decubitus ulcer treatment: a comparative study. *Yonsei Med J* 1996 Jun;37(3):181-185

*Reference 2:* Ohlsson P., Larsson K., Lindholm C., Moller M.A Comparison of saline-gauze and hydrocolloid treatment in a prospective, randomized study. *Scand J Prim Health Care* 1994 Dec;12(4):295-299

[^Top](#)

### Do hydrocolloid dressings reduce pain?

Pain is a feature of superficial wounds, such as skin graft donor sites, particularly at dressing changes.

One prospective randomized trial compared parafin gauze and a hydrocolloid dressing, applied on donor sites. The results showed that the hydrocolloid is a less painful dressing than parafin gauze, as well as achieving faster healing of skin graft donor sites [1].

In another study, which involved patients with lacerations, abrasions and minor operation incisions, compared a hydrocolloid dressing with a non-adherent dressing. While time to heal was similar for both groups, patients using the hydrocolloid experienced less pain, required less analgesia and were able to carry out their normal daily activities including bathing or showering without affecting the dressing or the wound. [2]

The precise mechanism involved in the hydrocolloid ability to reduce pain is not fully understood, but some possible explanations have been discussed. [3]

*Reference 1:* Cadier M. A., Clarke J. A. Derasorb versus Jelonet in patients with burns skin graft donor sites. *J Burn Care Rehabil* 1996 May;17(3):246-251

*Reference 2:* Heffernan A., Martin A. J. A comparison of a modified form of Granuflex (Granuflex Extra Thin) and a conventional dressing in the management of lacerations, abrasions and minor operation wounds in an accident and emergency department. *J Accid Emerg Med* 1994 Dec;11(4):227-230

*Reference 3:* Nemeth AJ, Eaglstein WH, Taylor JR, et al. Faster healing and less pain in skin biopsy sites treated with an occlusive dressing. *Archives of Dermatology*, Vol 127, November 1991, pp 1679- 1683.

[^Top](#)

### Is there any difference between brands?

Yes

There are many differences in structure, flexibility, dimensions, fluid handling properties and, probably, in other performance parameters. The trouble is, few studies have compared different brands [1]. Because of the shortage of *in vitro* research, and a complete lack of (published) *in vivo* research, manufacturers claims tend to be based on indirect comparisons such as comparisons based on rival studies which compared hydrocolloids and parafin gauze. One or two comparisons of 'patient satisfaction' have been published, but these have no clinical value. Or indeed any value at all, other than 'marketing exercises'.

*Reference 1* Thomas S., Loveless, P. A comparative study of the properties of twelve hydrocolloid dressings. *World Wide Wounds*, July 1997; [Full Text: <http://www.smtl.co.uk/World-Wide-Wounds/1997/july/Thomas-Hydronet/hydronet.html>]

[^Top](#)

### Is colour duplex imaging possible through hydrocolloid dressings?

Colour flow duplex scanning is an accepted method of determining the patency and haemodynamic status in infrainguinal grafts and native arteries. There are often dressings covering the leg above the vessel to be scanned.

A blinded study compared scanning normal superficial femoral arteries with scans when one of five commonly used dressings were applied to the skin above the artery, in random order. The blinded operator graded the signal produced on a linear analogue scale.

An absorbent material dressing and a bilaminate membrane dressing did not transmit ultra-sound at all. Two thin membrane dressings allowed excellent B-mode and colour flow images, in addition to clear Doppler signals. A thin hydrocolloid allowed a clear B-mode image of each artery to be visualised and an adequate Doppler waveform to be obtained. However colour flow mapping was less than optimal although it was possible in each of the arteries.

In patients who require dressings and who may require colour flow duplex scanning of vessels in the same area, a product that permits ultrasound transmission, thus saving the necessity of removing the dressing for the assessment, clearly has advantages

*Reference:* Whiteley M. S., Magee T. R., Harris R., Horrocks M., Eur J Vasc Surg 1993 Nov;7(6):713-716

[^Top](#)

### How effective are hydrocolloid dressings for partial thickness burns?

A study compared a hydrocolloid formulation with silver sulphadiazine/chlorhexidine parafin gauze dressings in the outpatient management of small partial skin thickness burns.

Burn wounds were followed until complete re-epithelialization occurred. There were no statistical differences between the groups, with respect to healing time, and patients' subjective responses to treatment.

However, dressing application (but not removal) was easier in the hydrocolloid group. Furthermore, the that group had significantly fewer dressing changes; a mean of three changes per subject group compared with eight in the silver sulphadiazine/chlorhexidine parafin gauze group. In this study, both modalities were found to be equally suitable and effective for small partial skin thickness burns.

*Reference:* Afilalo M., Dankoff J., Guttman A., Lloyd J., DuoDERM hydroactive dressing versus silver sulphadiazine/Bactigras in the emergency treatment of partial skin thickness burns. Burns 1992 Aug;18(4):313-316

[^Top](#)

### Are hydrocolloid dressings contraindicated in diabetes?

An open randomized controlled study was carried out in 44 patients with diabetes who had necrotic foot ulcers treated with adhesive zinc oxide tape or with an adhesive occlusive hydrocolloid dressing. Fourteen of the 21 patients treated with adhesive zinc oxide tape had their necrotic ulcers improved by at least 50%, compared to six out of 21 with the hydrocolloid dressing (statistically significant). Fifteen patients showed an increase in the area of necrosis during the course of the 5-week study and of these, 10 had been treated with the hydrocolloid dressing. [1]

However, these wounds were necrotic; other clinicians firmly recommend hydrocolloids, particularly for the protection of the wound after the removal of necrotic tissue. [2]

Foot ulcers in people with diabetes, often homogenised by the term diabetic ulcer, usually have both vascular and neuropathic aetiology; it would be unwise to assume that two apparently similar ulcers should be managed the same way. This issue has been controversial since the introduction of hydrocolloids; currently, the best advice would seem to be "use with caution in patients with diabetes."

*Reference 1:* Apelqvist J., Larsson J., Stenstrom A., Topical treatment of necrotic foot ulcers in diabetic patients: a comparative trial of DuoDerm and MeZinc. Br J Dermatol 1990 Dec;123(6):787-794[PubMed abstract]

*Reference 2:* Laing P., Diabetic foot ulcers. Am J Surg 1994 Jan;167(1A):31S-36S[PubMed abstract]

[^Top](#)

### What are the effects of a hydrocolloid dressing on bacterial growth?

Thirty patients with lower limb ulcers of different aetiologies were treated with an occlusive hydrocolloid dressing twice a week for a maximum period of 12 weeks. No antibacterial chemotherapy was utilized. A culture was taken of the exudate of the ulcer before commencement of treatment and weekly or bi-weekly thereafter.

The results showed a mixed flora with prevalence of *Staphylococcus aureus*. The average duration of the treatment period was 67 days. The average interval between dressing changes was 4.1 days. Subsequent bacterial cultures showed a persistence of the original flora, but there was no correlation between the type of flora present and clinical evidence of infection or between the type of flora present and the rate of healing of

the ulcer [1].

In another study, the bacterial flora of chronic venous ulcers treated with an occlusive hydrocolloid dressing were studied over eight weeks. The flora was generally stable. Once a species was present, it remained with the exception of *Pseudomonas*, which appeared to be inhibited by the dressing. Twelve out of 20 ulcers contained anaerobic bacteria and healing did not appear to be impaired by the presence of any particular species of bacteria [2].

*Reference 1:* Annoni F., Rosina M., Chiurazzi D., Ceva M., The effects of a hydrocolloid dressing on bacterial growth and the healing process of leg ulcers. *Int Angiol* 1989 Oct;8(4):224-228

*Reference 2:* Gilchrist B., Reed C., The bacteriology of chronic venous ulcers treated with occlusive hydrocolloid dressings. *Br J Dermatol* 1989 Sep;121(3):337-344

[^Top](#)

---

## Useful Resources

- A comparative study of the properties of twelve hydrocolloid dressings

---

All materials copyright © 1992-Feb 2001 by SMTL, March 2001 *et seq* by SMTL and MEP unless otherwise stated.

---

[| Home |](#) [Index |](#) [Mailing Lists |](#) [Subject Areas |](#) [MEP |](#) [SMTL |](#) [Site Map |](#) [Archive |](#) [Contact Us |](#)

Search:  | [Advanced search](#)

---

<http://www.worldwidewounds.com/1998/april/Hydrocolloid-FAQ/hydrocolloid-questions.html>  
Last Modified: Thursday, 29-Mar-2001 14:24:59 BST